Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pathogenicity of <i>P. gingivalis</i> strains carrying clusters of specific polymorphic variants of peptidylarginine deiminase gene.

Frontiers in cellular and infection microbiology·2026

Same author

Impact of Simulated Artifacts on the Classification Performance of Apical Views in Transthoracic Echocardiography Using Convolutional Neural Networks.

Bioengineering (Basel, Switzerland)·2026

Same author

Effect of SGLT2 Inhibitors on the Efficacy of First-Time Pulmonary Vein Isolation and Clinical Course of Patients with Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation.

Journal of cardiovascular development and disease·2026

Same author

Clinically Actionable Explainable AI in Pulmonary Arterial Hypertension: Endpoints, Calibration, and External Validation. Reply to Pagnoni et al. Toward Clinically Actionable Explainable AI in Pulmonary Arterial Hypertension: Endpoints, Calibration, and External Validation. Comment on "Ledziński et al. Personalized Medicine in Pulmonary Arterial Hypertension: Utilizing Artificial Intelligence for Death Prevention. <i>J. Clin. Med.</i> 2025, <i>14</i>, 8325".

Journal of clinical medicine·2026

Same author

Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.

ESC heart failure·2026

Same author

Designing the right trial for sacubitril / valsartan in heart failure with preserved ejection fraction-related pulmonary hypertension. Authors' reply.

Polish archives of internal medicine·2026

Search research articles

Related Experiment Video

Updated: May 28, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

ADAMTS13 Gene Polymorphisms and Coronary Artery Disease Risk, Long-Term Survival, and Risk Factor Profile.

Justyna Wrona¹, Anna Balcerzyk-Matić¹, Katarzyna Mizia-Stec²

¹Department of Biochemistry and Medical Genetics, Faculty of Health Sciences in Katowice, Medical University of Silesia, Medykow Street 18, 40-752 Katowice, Poland.

|May 27, 2026

Summary

Genetic variations in ADAMTS13 (a gene impacting blood clotting) do not influence coronary artery disease (CAD) risk or survival. However, these polymorphisms are linked to higher HDL cholesterol and altered lipid profiles, warranting further research into underlying mechanisms.

Keywords:

ADAMTS13 coronary artery disease long-term survival polymorphisms

Related Experiment Videos

Last Updated: May 28, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Area of Science:

Cardiovascular Genetics
Thrombosis and Hemostasis
Molecular Biology

Background:

ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13) cleaves von Willebrand factor, regulating platelet aggregation and thrombogenesis.
Low ADAMTS13 levels are potentially linked to increased cardiovascular event risk.
Polymorphisms in the ADAMTS13 gene may influence its activity and impact cardiovascular health.

Purpose of the Study:

To investigate the association between ADAMTS13 gene polymorphisms and the risk of coronary artery disease (CAD).
To evaluate the impact of these polymorphisms on patient survival following CAD diagnosis.
To explore potential correlations between ADAMTS13 variants, lipid profiles, and gene expression.

Main Methods:

Genotyping of ADAMTS13 polymorphisms (rs2301612, rs2073932, rs2285489) using TaqMan PCR.
Study cohort comprised 259 CAD patients and 238 control blood donors.
In silico analysis was employed to assess the influence of polymorphisms on gene expression.

Main Results:

No significant association was found between ADAMTS13 polymorphisms and CAD risk or long-term patient survival (5- and 10-year follow-up).
Carriers of specific alleles (G for rs2301612/rs2073932, T for rs2285489) exhibited higher HDL cholesterol levels.
Polymorphisms rs2285489 and rs2301612 were associated with certain proatherogenic lipid indices, and in silico analysis suggested effects on gene expression in vascular tissues and blood.

Conclusions:

ADAMTS13 gene polymorphisms may influence gene expression in specific tissues, but not sufficiently to impact CAD onset or survival.
A notable association exists between analyzed ADAMTS13 polymorphisms and HDL levels or specific proatherogenic lipid indices.
The precise mechanisms underlying the observed associations with lipid profiles require further investigation.